Six weeks into Ozempic, you have had four starter doses of 0.25 mg and two doses of 0.5 mg. That is the label's calendar,1 and it is why week 6 is early: the label says semaglutide needs 4 to 5 weeks of weekly doses to reach steady levels in the blood,2 so the 0.5 mg dose has not fully settled yet. No published trial we read reports Ozempic weight loss at exactly week 6. The closest measured points are a 12-week appetite trial on semaglutide up to 1 mg, where people lost 5.0 kg on average,6 and a Mayo Clinic cohort on the higher Wegovy doses that averaged 5.9% at three months.8
So the honest week-6 answer is a range of experiences, not a number: many people notice they eat less well before the scale moves much, stomach side effects tend to peak around the dose steps, and a slow start does not decide how the next months go. The rest of this page lays out each of those with its source.
Where you are on the label at week 6
Ozempic is approved for type 2 diabetes; weight loss is an off-label use. Wegovy is the same molecule approved for weight, with the same first eight weeks.4
| Week | Ozempic dose | Wegovy dose | What the label says about it |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.25 mg | A starting dose; the climb is there "to reduce the risk of gastrointestinal adverse reactions"1 |
| 5 to 6 | 0.5 mg | 0.5 mg | Week 6 is the second dose at this step14 |
| 7 to 8 | 0.5 mg | 0.5 mg | Ozempic can only go to 1 mg "after at least 4 weeks" at 0.5 mg1 |
| 9 and on | 0.5, 1 or 2 mg, set by blood sugar | 1 mg, then 1.7 mg, then the maintenance dose from week 17 | Wegovy allows "delaying dosage escalation for 4 weeks" if a step is not tolerated4 |
Two label facts explain why week 6 feels the way it does. Each injection peaks in the blood "1 to 3 days post dose", and steady-state exposure takes "4 to 5 weeks of once-weekly administration".2 By that arithmetic you are two weeks into a step that needs four or five to level out, on a dose that is a fraction of where most trials ended. Your prescriber may also move you more slowly than the minimum; the label sets the shortest path, not a deadline.
What studies measured near week 6
| Study | Who and what dose | When measured | Result |
|---|---|---|---|
| SURPASS J post hoc, 20259 | 893 adults with type 2 diabetes in Japan, tirzepatide (Mounjaro's molecule) | Week 8, after 4 weeks each at 2.5 and 5 mg | 23.5% had lost 5% or more; 76.5% had not |
| Blundell, 20176 | 30 adults with obesity, semaglutide escalated to 1.0 mg | Week 12 | 5.0 kg average loss, "predominantly from body fat mass"; 24% less eaten across a day of free meals vs placebo |
| Ghusn (Mayo Clinic), 20228 | 175 adults, semaglutide 1.7 or 2.4 mg, routine care | 3 months | 5.9% average loss; 3.9% with type 2 diabetes vs 6.3% without |
| Friedrichsen, 20217 | 72 adults with obesity, escalated to 2.4 mg | Week 20 | 9.9% vs 0.4% on placebo; 35% less eaten at a free lunch |
| Ghusn (Mayo Clinic), 20228 | 102 adults still followed | 6 months | 10.9% average loss |
Read the table as a curve, not a promise. The early points are small studies, two of them run or co-authored by the makers,679 and the 12-week trial used the Ozempic dose range while the cohort used Wegovy doses. They agree on the shape: modest losses by the end of month two or three that keep growing for months after. For where the long trials ended, at weeks 68 and 72, see how long GLP-1s take to work.
What the first six weeks usually feel like
Eating less, before the scale says much
The mechanism the appetite trials measured is intake. At 12 weeks, semaglutide brought "less hunger and food cravings, better control of eating and a lower preference for high-fat foods", and total intake across a day of free meals fell 24% against placebo.6 At week 20 on the higher dose, people ate 35% less at a free lunch.7 Those were measured after the starter weeks, so they say little about week 2, but many people describe the quieter appetite first; see food noise for what that research shows.
Stomach side effects around the dose steps
Week 5 is the first dose increase, and the labels say that is when the stomach is most likely to object. In Ozempic's pooled trials, stomach side effects hit 32.7% of people on 0.5 mg and 36.4% on 1 mg against 15.3% on placebo, and "the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation."3 On Wegovy's weight trials, nausea reached 44% vs 16% on placebo and vomiting 25% vs 6%.5 The nausea, constipation and diarrhea guide covers what helps, and Ozempic side effects has the full list.
Blood sugar, for people taking it for diabetes
The label gives no week-6 glucose figure; its own pharmacodynamic tests ran "after 12 weeks of treatment (including dose escalation)".2 The 3-month weight results were smaller in people with type 2 diabetes in the Mayo cohort, 3.9% vs 6.3%.8
Not losing much by week 6
This is the question behind most "6 week results" searches. Three things from the sources are worth knowing.
- Most people in the week-8 study had not reached 5% yet. In the tirzepatide analysis, 76.5% had lost less than 5% at week 8, and that group still had "clinically significant reductions" over 52 weeks, though smaller than the early group.9
- Early response does predict, loosely. A 2026 review calls "early on-treatment response" the "most readily actionable predictor currently available", and says "no single baseline characteristic reliably predicts response."10
- True non-response is uncommon in trials. The same review puts it, defined as less than 5% loss, at "approximately 10% of participants in controlled trials", higher in real-world practice.10
If you are worried about your pace, bring it to your prescriber with your weekly weights. Whether to hold, raise or switch a dose is their call, and the labels give them room to go slower.14
How the other GLP-1s compare at the same point
| Medicine | Weeks 1 to 4 | Weeks 5 to 8 | Note |
|---|---|---|---|
| Ozempic | 0.25 mg1 | 0.5 mg1 | Approved for type 2 diabetes |
| Wegovy injection | 0.25 mg4 | 0.5 mg4 | Same molecule and same start, approved for weight |
| Zepbound and Mounjaro (tirzepatide) | 2.5 mg11 | 5 mg11 | The week-8 data above are on this schedule9 |
Compounded semaglutide has no FDA label of its own, so the calendar above is the branded one. Doses by week for every brand are in the Ozempic dosage chart.
If you stop at week 6
Semaglutide does not leave at once: with a half-life of about a week, the label says it "will be present in the circulation for about 5 weeks after the last dose."2 What happens to weight after stopping is covered in stopping a GLP-1 and weight regain.
What it costs to keep going
On our board today the cheapest cash GLP-1 program is $69 a month, compounded semaglutide starts at $69, and the middle of the board is $158. A licensed clinician decides whether you qualify, and compounded versions are not FDA approved.
For off-label use and what weight programs charge for it, see Ozempic for weight loss and cheapest semaglutide, checked against the sellers' own pages.
